Edition:
United Kingdom

Poxel SA (POXEL.PA)

POXEL.PA on Paris Stock Exchange

7.02EUR
21 Sep 2018
Change (% chg)

€0.19 (+2.78%)
Prev Close
€6.83
Open
€6.94
Day's High
€7.10
Day's Low
€6.93
Volume
129,350
Avg. Vol
55,594
52-wk High
€8.18
52-wk Low
€5.19

Summary

Name Age Since Current Position

Pierre Legault

56 2016 Chairman of the Board

Thomas Kuhn

Chief Executive Officer, Director

Pascale Malgouyres

Business Development and Marketing Director, Co-Founder

Anne Renevot

2017 Chief Financial Officer

Jonae Barnes

2016 Senior Vice President, Investor Relations and Public Relations

Takashi Kaneko

2018 Senior Vice President Medical, President of Poxel Japan K.K

Eric Massou

2017 Chief Administrative Officer

Isabelle Tronel

Project Manager and Administration Officer

Sébastien Bolze

Scientific Director

Sophie Bozec

Director of Research (Diabetes)

Pascale Fouqueray

Medical Director

Janice Bourque

2016 Director

Thierry Hercend

2016 Director

Laurent Higueret

Director

Olivier Martinez

Director - Representative of Bpifrance Investissement

Bruno Montanari

Director - Representative of OMNES Capital

Kumi Sato

2017 Director

Raphael Wisniewski

45 Director - Representative of Edmond de Rothschild Investment Partners

Mohammed Baluch

Independent Director

Biographies

Name Description

Pierre Legault

Mr. Pierre Legault has served as Chairman of the Board of Poxel S.A. since April 18, 2016. He served as Director of the Company between February 1, 2016 and April 18, 2016. He joined Poxel with over 35 years of experience working in the pharmaceutical and biotechnology industry. Since 2012, he has been the Executive Chairman and later became President and CEO of NephroGenex, a North Carolina-based biotechnology company focused on diabetic nephropathy and acute kidney injury. He was responsible for the company's successful IPO to the Nasdaq in 2014 as well as the initiation of a Phase 3 development program. From 2010 to 2012, he was President and CEO of Prosidion Ltd, which specialized in the treatment of diabetes and obesity. In 2009/2010, he was Executive Vice President, Chief Financial Officer and Treasurer of OSI Pharmaceuticals. From 2006 to 2007, Pierre was President of Eckerd Pharmacies. Between 1989 and 2005 he held various roles at legacy companies of Sanofi-Aventis, leading up to the position as Worldwide President Dermatology/Dermick which he held from 2003 to 2005. Pierre studied International Finance, Business & Commerce and earned a Masters of Business Administration degree in Marketing from McGill University in Montreal, Canada. He holds a Bachelor of Business Administration degree from Hautes Etudes Commerciales.

Thomas Kuhn

Mr. Thomas Kuhn is Chief Executive Officer, and a Director of Poxel SA. He joined Merck Serono in 2000, where he held various positions in clinical development mainly for diabetes products. Between 2004 and 2007, he directed global R&D projects, with two products being in phase 2clinicaltrials, and Life Cycle Management projects, specifically for Glucophage, a diabetes treatment. With the integration of Serono in 2007, he was involved in refining the Merck Serono strategy, which led to the divestment of diabetes as an integrated therapeutic area. He was involved in the establishment of Poxel SA. Mr. Kuhn received his pharmacy degree from University of Lyon I(France) and his MBA from Ashridge University.

Pascale Malgouyres

Ms. Pascale Malgouyres is Business Development and Marketing Director and Co-Founder at Poxel SA. She started her career at the French affiliate of Eli Lilly as a clinical research associate, subsequently moving to the sales department. She then joined Procter & Gamble Pharmaceuticals, where she was responsible for marketing programs in rheumatology. She joined Merck KGaA in 1992, where she held various positions in national and international marketing departments. She has focused on diabetes since 2001 as a marketing contributor to the global product teams in charge of three different new chemical entities (NCEs) in development. In this capacity, she developed a comprehensive approach to channel marketing input towards research, and she developed methods to produce business cases. Her last position at Merck Serono was Global Marketing Director of the Glucophage franchise. She received a pharmacy degree from the University of Lyon I (France) as well as an MSc in clinical pharmacokinetics.

Anne Renevot

Ms. Anne Renevot is Chief Financial Officer of the Company. Prior to joining Poxel, Anne Renevot served as CFO of EOS Imaging where she played a key role in EOS' successful IPO on Euronext Paris, which raised €39M. At EOS Imaging, Ms. Renevot helped to raise capital through private placements, equity lines and debt offerings. She was responsible for financial regulatory compliance, financial planning and communications, and she also held leading roles in the Company's acquisitions and partnerships. Before her appointment at EOS Imaging, Ms. Renevot served at Cartier, a luxury goods company, as CFO of Cartier Joaillerie Manufacturing Division and as International Financial Controller. Earlier in her career, Ms. Renevot served as Manager at EY Audit and as a Division Controller at Legris Industries. Anne Renevot received a bachelor's degree in finance from Audencia Business School in Nantes, France and a master's degree in corporate finance from Ohio State University, Columbus, Ohio.

Jonae Barnes

Ms. Jonae R. Barnes has been Senior Vice President, Investor Relations and Public Relations of POXEL S.A. since March 14, 2016. She has 20 years of experience in the pharmaceutical and biotechnology industry. She began her career at Sepracor (now Sunovion Pharmaceuticals; acquired by Dainippon Sumitomo Pharma Co.), a specialty pharmaceutical company, where she held a series of progressively responsible management and executive roles over a 14-year period and most recently served as Senior Vice President, Investor Relations, Corporate Communications and Internal Communications. Ms. Barnes has also served in senior leadership roles at Agenus, an immuno-oncology company and Vision Medicines, an ophthalmology-focused company. In addition to her corporate appointments, she has advised privately held and publicly traded biotech companies through her investor relations consulting practice in the therapeutic areas of respiratory disorders, infectious diseases, IBS, diabetes and oncology. She holds a Bachelors degree in Political Science from Suffolk University and Masters degrees in Financial Economics and Multinational Commerce from Boston University.

Takashi Kaneko

Dr. Takashi Kaneko M.D., Ph.D., has been Senior Vice President Medical and President of Poxel Japan K.K at Poxel SA since September 1, 2018. He has 33 years of experience including pharmaceutical industry experience with a focus on medical affairs and clinical development ranging from product evaluation, development and post-commercial launch, and clinical practice and medical research experience. Dr. Kaneko joined Poxel from Janssen Pharmaceutical K.K., where he was Head of Medical Affairs. Prior to Janssen Pharmaceutical K.K., he was the Department Head of the Medical Excellence Department in the Medical Division at Novartis K.K. Dr. Kaneko also held several senior-level positions at Santen, which included the areas of Compliance, Global Clinical Development and Medical Affairs, Head of Global Research and Development as well as other research and development-related positions. In addition, he was a Vice President, Medical Director at Sanofi-Aventis K.K., and served in clinical development roles at Bristol-Myers K.K., BMS, Japan. Dr. Kaneko holds an MD and PhD degree from the University of Tokyo.

Eric Massou

Mr. Eric Massou is Chief Administrative Officer of Poxel SA. He has a 16 years' experience as external auditor at Mazars and Ernst & Young (nine years) where he was mainly in charge of industrial groups (referred work) such as Becton Dickinson (medical supplies), Black & Decker (manufacturing), Brenntag (distribution of chemicals) or Candia (food). He also had an experience of financial controller (five years) and Group CFO (two years) in a plastic packaging company named Veriplast Packaging. There, he was involved in all recurrent financial aspects (reporting in local, UK Gaap and IFRS, budgets, consolidation, cash management, IT, legal, tax planning, cost control) and monitored two vendor due diligence to welcome Charterhouse in 2004 and SUN in 2007 as new shareholders. In addition, he was in the deal team for all M&A activities (two add-ons completed in September 2010, non-core businesses disposals in Holland and Spain, assets disposals in France, Spain, Holland and Bulgaria). He was in charge of external stakeholders: financial communication with banks, credit insurers, local tax authorities and PWC as local and group auditor. He raised new monies (leasing, loans, shareholder's contribution, factoring) to support the business growth and finance new industrial capex. Mr. Massou received a Master in Finance at the BESS program of Trinity College Dublin (Ireland) as well as the French CPA (Chartered Public Accountant).

Isabelle Tronel

Ms. Isabelle Tronel serves as Project Manager and Administration Officer at Poxel SA. She started her career in 1989 in the service industry as Front Desk Manager for a four star hotel. She joined Merck KGaA in 1996 as Project Assistant for global product development in the CardioMetabolic Care area. She ensured all budgeting, controlling and logistic activities for a global team. She became Project Manager in 2007, ensuring team coordination and project planning for a Phase III product.

Sébastien Bolze

Mr. Sebastien Bolze is Scientific Director of Poxel SA. He is a Doctor of Pharmacy in Lyon. He has 15 years of experience in the pharmaceutical industry (Merck Serono, Fournier Pharma, Solvay Pharmaceuticals).

Sophie Bozec

Ms. Sophie Bozec is Director of Research (Diabetes) at Poxel SA. She graduated from Paris VII with a Doctorate degree in Biology. She has 16 years of experience in the field.

Pascale Fouqueray

Mr. Pascale Fouqueray is Medical Director of Poxel SA. He is a Doctor of Medicine (Angers-France), Endocrinologist (Paris-France) and Doctor of Sciences (Paris-France). He has 14 years of experience in the pharmaceutical industry (Merck Serono). He is head of exploratory clinical development of molecules in diabetes, obesity and gout at Merck Serono.

Janice Bourque

Ms. Janice Bourque is Director of the Company. She serves as Managing Director of Hercules Technology Growth Capital, and Pierre Legault. Janice Bourque has been Managing Director, Life Sciences at Hercules Technology Growth Capital, a technology and life science specialty finance company, since 2010. During this time she helped early and expansion stage biotechnology companies to secure financings with investments ranging from $10 million to $60 million per company. Prior to this, she was a consultant at Commons Capital where she advised and provided strategic corporate investor fundraising. From 2005 to 2009 she was the Senior Vice President and Group Head-Life Sciences at Comerica Bank in Dallas, Texas. Janice was also President and CEO of the Massachusetts Biotechnology Council, the oldest biotechnology trade association in the world, where she was instrumental in its growth since 1992. She currently serves as Board member and Audit Committee Chair at The Village Bank and is an Emeritus member of the Leadership Council for MIT Koch Institute for Integrative Cancer Research. Janice graduated from the University of New Hampshire with an MBA in Finance and Accounting.

Thierry Hercend

Dr. Thierry Hercend has served as Director of Poxel S.A. since April 18, 2016. He served as Chairman of the Board of the Company until April 18, 2016. He has over 30 years of both academic and pharmaceutical experience in various therapeutic areas including oncology and inflammatory diseases. Since 2006, Dr. Hercend has been Venture Partner at Edmond de Rothschild Investment Partners (EdRIP). From 2002 until 2005, Dr. Hercend was Vice President in charge of the oncology therapeutic area at Aventis. From 1998 to 2002, he was Vice President of Research, Europe, at Vertex Pharmaceuticals. Previously, Dr. Hercend was Head of Research and Development for the Laboratory of Plasma Fractionation and Biotechnology (LFB) and was in various executive R & D positions with Roussel-Uclaf. Prior to joining the pharmaceutical industry, Dr. Hercend was Head of the Immunology unit of the Gustave Roussy Cancer Institute, Villejuif, France, Director of the Inserm unit U333 dedicated to tumor Immunology and a Professor of Immunology at the Medical Faculty of Paris XI University. He has authored more than 120 publications in oncology, auto-immune diseases and transplantation. He holds a Doctorate in Philosophy degree from Universite de Paris.

Laurent Higueret

Mr. Laurent Higueret is Board Member of Poxel SA. He is Investments Director at Bpifrance Participations. He joined Large Venture pole Bpifrance early 2014 as Director of Investment, focusing primarily on investments in the health field. He currently serves on the Boards of Poxel and TxCell, and follows Bpifrance of interests in Cerenis and DBV Technologies companies. Previously, he was an investment banker for six years in the M & A team of Health BNP Paribas, and also created a startup in the field of health services. He is Doctor of Pharmacy from the University of Bordeaux and also holds a Master in Finance from EM Lyon Business School.

Olivier Martinez

Dr. Olivier Martinez is Board Member - Representative of Bpifrance Investissement at Poxel SA. He is also Investments Director of Bpifrance Investissement. Dr. Martinez graduated from Ecole Normale Superieure and College des Ingenieurs. He obtained his PhD degree in Cellular Biology from Universite Paris XI. From 1992 to 1997, Dr. Martinez was student researcher at the Institut Pasteur and the Institut Curie in the field of cell biology. After training in management, Dr. Martinez joined the group of Life Sciences Gemini Consulting, where for two years he devoted himself to projects of pharmaceutical and health. In 2000, he joined Bioam Management as Business Manager and was appointed Investment Director and Executive Board member in 2004.

Bruno Montanari

Mr. Bruno Montanari is Board Member - Representative of OMNES Capital of Poxel SA. He is Investments Director at OMNES Capital. Mr. Montanari began his career in 1999 in London in investment banking at Deutsche Bank and Merrill Lynch before joining the first capital risk at CDP Capital then at Atlas Venture in 2004. Mr. Montanari graduated with Master degree in Strategic Management from HEC and Doctor of Pharmacy (Paris V).

Kumi Sato

Ms. Kumi Sato serves as Director of the Company. For over 30 years, Kumi Sato has served as President and CEO of Cosmo Public Relations Corporation, an award-winning strategic communications and public affairs firm based in Tokyo, Japan, with a specialized healthcare division, COSMO Healthcare. Since its founding, COSMO has consulted for over 500 companies in healthcare, food and food sciences, and the service industry. Before taking over as CEO in 1987, she founded COSMO International, which advised Japanese companies on US market entry strategies. During her time at COSMO, she has been instrumental in directing the company to broaden its international focus and has held a series of noteworthy advisor positions, such as President and Founder of Women Japan.com and Outside Director for Rokko & Associates Inc. In 2010, she founded BioCube, a think-tank to discuss Japan's healthcare system and biotech-related topics. She currently serves as an advisor to the Global Health Innovative Technology Fund in Tokyo, a lecturer at the Graduate School of Business Breakthrough University and is Chairman Emeritus of the American Chamber of Commerce in Japan. In addition, she is co-chairman of the Global Council for the Asia Society, based in New York. Ms. Sato has also authored two business textbooks on communication strategies and corporate social responsibility. Ms. Sato started her career at McKinsey & Co., New York and holds a B.A. in East Asian Studies from Wellesley College, MA.

Raphael Wisniewski

Mr. Raphael Wisniewski is Director - Representative of Edmond de Rothschild Investment Partners at Poxel SA. Mr. Wisniewski joined the team of Life Sciences at Edmond de Rothschild Investment Partners in 2001 where he participated in more than twenty investments in European or US biotech firms, medical technology and molecular diagnostics. He previously worked in London in the Healthcare Corporate Finance division at Salomon Smith Barney and Goldman Sachs in the financial department of the British private clinics of Generale de Sante. He is a graduate of HEC and Institut d.Etudes Politiques de Paris (Finance and Economics).

Mohammed Baluch

Mr. Mohammed Khoso Baluch is Independent Board Member of Poxel SA. He is Senior Vice President and President of Europe at UCB. Prior to joining UCB, Mr. Baluch worked for Eli Lilly & Co. for 24 years in various positions across Europe, the Middle East and the United States within the Management Committee, as head of business development, market access or product leadership. Mr. Baluch was also named vice president of American unity "Diabetes and Family Health" within the position he held at Lilly. He was also a member of the Council in the Indiana Division of the American Foundation.